Fig. 1

Distinct temporal regulation of ECM in response to drug treatment and in vitro culture conditions. a RNA sequence data show that FN is upregulated in melanoma cell lines and patients who have become resistant as a result of multiple drug treatments. Bar charts showing RNA sequence counts for control melanocytes compared to seven melanoma cell lines treated with BRAF inhibitor, where the red line shows the basal level of controls. b RNAseq-based expression levels for patients that were biopsied pre- and post-vemurafenib (red), dabrafenib (blue), and trametinib (green) treatment. c Schematics of experimental protocol using MS to identify secretomes of the isogenic human melanoma clones. d Dynamics of secreted ECM components show that temporal evolution of tumor biofilm differs as a function of tumor heterogeneity in cell culture. Quantitative comparison of ECM proteins in conditioned media reveals temporal differences in the amount of secreted proteins, highlighting the heterogeneity of baseline ECM biogenesis. * indicates a p value < 0.05, ** indicates a p value < 0.01 and *** indicates a p value < 0.001